146 related articles for article (PubMed ID: 11330471)
21. Debio 0507 primarily forms diaminocyclohexane-Pt-d(GpG) and -d(ApG) DNA adducts in HCT116 cells.
King CL; Ramachandran S; Chaney SG; Collins L; Swenberg JA; DeKrafft KE; Lin W; Cicurel L; Barbier M
Cancer Chemother Pharmacol; 2012 Mar; 69(3):665-77. PubMed ID: 21968950
[TBL] [Abstract][Full Text] [Related]
22. Interactions of oxaliplatin with the cytoplasmic thiol containing ligand glutathione.
Shoeib T; Sharp BL
Metallomics; 2012 Dec; 4(12):1308-20. PubMed ID: 23128601
[TBL] [Abstract][Full Text] [Related]
23. Model platinum nucleobase and nucleoside complexes and antitumor activity: X-ray crystal structure of [PtIV(trans-1R,2R-diaminocyclohexane)trans-(acetate)2(9-ethylguanine)Cl]NO3.H2O.
Ali MS; Khan SR; Ojima H; Guzman IY; Whitmire KH; Siddik ZH; Khokhar AR
J Inorg Biochem; 2005 Mar; 99(3):795-804. PubMed ID: 15708801
[TBL] [Abstract][Full Text] [Related]
24. Intraliposomal chemical activation patterns of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II) (L-NDDP)-a potential antitumour agent.
Maclean DS; Khokhar AR; Tyle P; Perez-Soler R
J Microencapsul; 2000; 17(3):307-22. PubMed ID: 10819419
[TBL] [Abstract][Full Text] [Related]
25. Early biotransformations of oxaliplatin after its intravenous administration to cancer patients.
Allain P; Heudi O; Cailleux A; Le Bouil A; Larra F; Boisdron-Celle M; Gamelin E
Drug Metab Dispos; 2000 Nov; 28(11):1379-84. PubMed ID: 11038167
[TBL] [Abstract][Full Text] [Related]
26. Conformer distribution in (cis-1,4-DACH)bis(guanosine-5'-phosphate)platinum(II) adducts: a reliable model for DNA adducts of antitumoral cisplatin.
Ranaldo R; Margiotta N; Intini FP; Pacifico C; Natile G
Inorg Chem; 2008 Apr; 47(7):2820-30. PubMed ID: 18284193
[TBL] [Abstract][Full Text] [Related]
27. 2.4 A crystal structure of an oxaliplatin 1,2-d(GpG) intrastrand cross-link in a DNA dodecamer duplex.
Spingler B; Whittington DA; Lippard SJ
Inorg Chem; 2001 Oct; 40(22):5596-602. PubMed ID: 11599959
[TBL] [Abstract][Full Text] [Related]
28. Cytotoxicity of platinum(IV) and platinum(II) complexes containing 1R,2R-cyclohexanediamine as a ligand.
Yamashita T; Hirose J; Noji M; Saito R; Tomida H; Kidani Y
Biol Pharm Bull; 1993 Oct; 16(10):1014-8. PubMed ID: 8287030
[TBL] [Abstract][Full Text] [Related]
29. Synthesis, antiproliferative activity in cancer cells and DNA interaction studies of [Pt(cis-1,3-diaminocycloalkane)Cl
Hoeschele JD; Kasparkova J; Kostrhunova H; Novakova O; Pracharova J; Pineau P; Brabec V
J Biol Inorg Chem; 2020 Sep; 25(6):913-924. PubMed ID: 32851480
[TBL] [Abstract][Full Text] [Related]
30. Displacement of the bidentate malonate ligand from (d,l-trans-1,2-diaminocyclohexane)malonatoplatinum(II) by physiologically important compounds in vitro.
Mauldin SK; Plescia M; Richard FA; Wyrick SD; Voyksner RD; Chaney SG
Biochem Pharmacol; 1988 Sep; 37(17):3321-33. PubMed ID: 3401260
[TBL] [Abstract][Full Text] [Related]
31. Effects of the bidentate malonate ligand on the utilization and cytotoxicity of platinum compounds in the L1210 cell line.
Mauldin SK; Husain I; Sancar A; Chaney SG
Cancer Res; 1986 Jun; 46(6):2876-82. PubMed ID: 3698013
[TBL] [Abstract][Full Text] [Related]
32. MutS preferentially recognizes cisplatin- over oxaliplatin-modified DNA.
Zdraveski ZZ; Mello JA; Farinelli CK; Essigmann JM; Marinus MG
J Biol Chem; 2002 Jan; 277(2):1255-60. PubMed ID: 11705991
[TBL] [Abstract][Full Text] [Related]
33. Oxaliplatin and its enantiomer induce different condensation dynamics of single DNA molecules.
Zhang HY; Liu YR; Ji C; Li W; Dou SX; Xie P; Wang WC; Zhang LY; Wang PY
PLoS One; 2013; 8(8):e71556. PubMed ID: 23951187
[TBL] [Abstract][Full Text] [Related]
34. Intracellular biotransformation of platinum compounds with the 1,2-diaminocyclohexane carrier ligand in the L1210 cell line.
Mauldin SK; Gibbons G; Wyrick SD; Chaney SG
Cancer Res; 1988 Sep; 48(18):5136-44. PubMed ID: 3409241
[TBL] [Abstract][Full Text] [Related]
35. Cellular and molecular aspects of drugs of the future: oxaliplatin.
Di Francesco AM; Ruggiero A; Riccardi R
Cell Mol Life Sci; 2002 Nov; 59(11):1914-27. PubMed ID: 12530522
[TBL] [Abstract][Full Text] [Related]
36. Role of DNA replication in carrier-ligand-specific resistance to platinum compounds in L1210 cells.
Gibbons GR; Kaufmann WK; Chaney SG
Carcinogenesis; 1991 Dec; 12(12):2253-7. PubMed ID: 1747924
[TBL] [Abstract][Full Text] [Related]
37. Modulation of cytotoxicity and cellular pharmacology of 1,2-diaminocyclohexane platinum (IV) complexes mediated by axial and equatorial ligands.
Kido Y; Khokhar AR; al-Baker S; Siddik ZH
Cancer Res; 1993 Oct; 53(19):4567-72. PubMed ID: 8402629
[TBL] [Abstract][Full Text] [Related]
38. Multi-Acting Mitochondria-Targeted Platinum(IV) Prodrugs of Kiteplatin with α-Lipoic Acid in the Axial Positions.
Savino S; Marzano C; Gandin V; Hoeschele JD; Natile G; Margiotta N
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30011897
[TBL] [Abstract][Full Text] [Related]
39. Influence of Ring Modifications on Nucleolar Stress Caused by Oxaliplatin-Like Compounds.
McDevitt CE; Guerrero AS; Smith HM; DeRose VJ
Chembiochem; 2022 Jul; 23(14):e202200130. PubMed ID: 35475312
[TBL] [Abstract][Full Text] [Related]
40. Role of carrier ligand in platinum resistance in L1210 cells.
Gibbons GR; Page JD; Mauldin SK; Husain I; Chaney SG
Cancer Res; 1990 Oct; 50(20):6497-501. PubMed ID: 2208108
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
